A Real-world Data (RWD) of the efficacy and
safety of Rivoceranib (apatinib) in Hepatocellular Carcinoma (HCC) was
presented in the poster at the American Association for Cancer Research (AACR) Annual
Meeting 2022 being held in New Orleans, Louisiana, from April 8-13.
With the support of Jiangsu Hengrui
Medicine (Hengrui), a total of 233 patients who received mono or combined therapy
of Rivoceranib with other treatments including TACE and chemotherapy were
enrolled in the study across China, including Shandong First Medical University.
As a result, 8 patients achieved complete
response (CR), illustrating an Overall Response Rate (ORR) of 30.90% and a
Disease Control Rate (DCR) of 82.40%. Median PFS (mPFS) and Overall Survival (mOS)
were 6.93 months and 11.36 months respectively and the high efficacy and safety
of Rivoceranib has once again been demonstrated.
Rivoceranib was approved as an HCC secondary
treatment in December of 2020 following a late-stage gastric cancer (GC)
treatment in China and is currently on sale. As a result of phase 3 clinical
trials of HCC, it was confirmed that the survival rate of 400 patients was
significantly improved, and the results were listed in the medical journal ‘The
Lancet Gastroenterology & Hepatology’.
HLB is currently conducting phase 3 global clinical trials in
combination with Hengrui's Camrelizumab (anti-PD-1 monoclonal antibody) to
develop Rivoceranib as an HCC primary treatment. Both Rivoceranib and
Camrelizumab were individually licensed for sale in China, so synergy effect between the two drugs is highly
expected.
Meanwhile, HLB has announced plans to file for NDA for two cases within a year. As HLB is the only Korean company that has entered the NDA stage with a global anticancer drug substance for two to three indications, it draws keen attention both at home and abroad.